NKTR Insider Trading Activity and SEC Form 4 Filings
NKTR insider trading summary
Over the past 12 months, insiders at Nektar Therapeutics (NKTR) reported 16 sales worth $2.4M by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.4M.
Latest NKTR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sell | $13K (186 @ $71.98) |
| Aug 18, 2026 | Howard W Robin | President & CEO | Sell | $30K (418 @ $71.98) |
| Jun 30, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sell | $398K (5,681 @ $70.00) |
| Jun 17, 2026 | Howard W Robin | President & CEO | Sell | $277K (4,500 @ $61.65) |
| Jun 17, 2026 | Howard W Robin | President & CEO | Sell | $334K (5,500 @ $60.81) |
| Jun 16, 2026 | Howard W Robin | President & CEO | Sell | $318K (5,303 @ $59.97) |
| Jun 16, 2026 | Howard W Robin | President & CEO | Sell | $285K (4,697 @ $60.71) |
| Jun 15, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sell | $336K (5,538 @ $60.71) |
| May 19, 2026 | Howard W Robin | President & CEO | Sell | $29K (444 @ $65.51) |
| May 19, 2026 | Jonathan Zalevsky | Chief R&D Officer | Sell | $13K (199 @ $65.51) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.